ArticleProgress in brain research2010
The impact of genetic research on our understanding of Parkinson's disease.
Article in Progress in brain research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Glycation at the Crossroads of Disease Pathogenesis: Mechanistic Insights and Therapeutic Frontiers.Diseases (Basel, Switzerland) · 2026Review
- Studying the effect of alpha-synuclein and Parkinson's disease linked mutants on inter pathway connectivities.Scientific reports · 2021Article
- The Female Impact in the World of Neurodegeneration.Frontiers in integrative neuroscience · 2021Article
- Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism.Scientific reports · 2020Article
- ATP13A2 Gene Variants in Patients with Parkinson's Disease in Xinjiang.BioMed research international · 2020Article
- Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins.PloS one · 2019Article
- Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.Experimental and therapeutic medicine · 2015Article
- The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.Cellular & molecular biology letters · 2014Review
- Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.Behavioral neuroscience · 2014Article
- Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.Neurobiology of disease · 2013Article
- Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.Neuroscience letters · 2013Article
- Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease.Molecular neurobiology · 2013Review
- The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease.Frontiers in computational neuroscience · 2013Article
- Living on the edge with too many mouths to feed: why dopamine neurons die.Movement disorders : official journal of the Movement Disorder Society · 2012Article
- Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.Human molecular genetics · 2011Article
- A guide to neurotoxic animal models of Parkinson's disease.Cold Spring Harbor perspectives in medicine · 2011Review
- Animal models of human genetic diseases: do they need to be faithful to be useful?Molecular genetics and genomics : MGG · 2011Review
- Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Progress in brain research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Until recently, genetics was thought to play a minor role in the development of Parkinson's disease (PD). Over the last decade, a number of genes that definitively cause PD have been identified, which has led to the generation of disease models based on pathogenic gene variants that recapitulate many features of the disease. These genetic studies have provided novel insight into potential mechanisms underlying the aetiology of PD. This chapter will provide a profile of the genes conclusively linked to PD and will outline the mechanisms of PD pathogenesis implicated by genetic studies. Mitochondrial dysfunction, oxidative stress and impaired ubiquitin-proteasome system function are disease mechanisms that are particularly well supported by genetic studies and are therefore the focus of this chapter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.